Coherus Oncology, Inc. (CHRS) Total assets 2016–2025
Coherus Oncology, Inc. (CHRS) total assets at each fiscal year-end, per SEC filings.
$258.3MFY2025 · since FY2016: $178.5M → $258.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $258.3M | -42.4% |
| FY2024 | $448.5M | -28.8% |
| FY2023 | $629.6M | +30.9% |
| FY2022 | $480.8M | -29.2% |
| FY2021 | $679.3M | -19.3% |
| FY2020 | $841.6M | +105.8% |
| FY2019 | $408.9M | +311.1% |
| FY2018 | $99.5M | -38.8% |
| FY2017 | $162.6M | -8.9% |
| FY2016 | $178.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating marginCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →